Share on StockTwits

CorMedix (NASDAQ:CRMD) CEO Randy Milby acquired 3,140 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were purchased at an average cost of $1.99 per share, for a total transaction of $6,248.60. Following the acquisition, the chief executive officer now directly owns 12,122 shares of the company’s stock, valued at approximately $24,123. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of CorMedix (NASDAQ:CRMD) remained flat at $2.0899 during during mid-day trading trading on Wednesday. The stock had a trading volume of 47,352 shares. CorMedix has a 52-week low of $0.66 and a 52-week high of $3.20. The stock’s 50-day moving average is $1.90 and its 200-day moving average is $1.98. The company’s market cap is $46.0 million.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Wednesday, August 20th. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.13. Analysts expect that CorMedix will post $-1.17 EPS for the current fiscal year.

A number of research firms have recently commented on CRMD. Analysts at Zacks downgraded shares of CorMedix to a “neutral” rating in a research note on Monday, July 28th. They now have a $2.20 price target on the stock. Analysts at Roth Capital initiated coverage on shares of CorMedix in a research note on Thursday, July 24th. They set a “buy” rating and a $3.00 price target on the stock.

CorMedix Inc (NASDAQ:CRMD) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.